Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials


Por: Bissonnette, R, Fernandez-Penas, P, Puig, L, Mendelsohn, AM, Rozzo, SJ, Menter, A

Publicada: 1 ene 2020 Ahead of Print: 1 ago 2019
Resumen:


Filiaciones:
Bissonnette, R:
 Innovaderm Res, Montreal, PQ, Canada

Fernandez-Penas, P:
 Westmead Hosp, Dept Dermatol, Westmead, NSW, Australia

 Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

Puig, L:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

Mendelsohn, AM:
 Sun Pharmaceut Ind Inc, Princeton, NJ USA

Rozzo, SJ:
 Sun Pharmaceut Ind Inc, Princeton, NJ USA

Menter, A:
 Texas A&M Coll Med, Baylor Scott & White, Div Dermatol, Dallas, TX USA
ISSN: 09269959





JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Letter
Volumen: 34 Número: 1
Páginas: 21-24
WOS Id: 000484203800001
ID de PubMed: 31403725

MÉTRICAS